The U.S. Patent & Trademark Office is paving the way for generic challengers to J&J’s prostate cancer drug Zytiga.
The U.S. Patent & Trademark Office is paving the way for generic challengers to J&J’s prostate cancer drug Zytiga (abiraterone). The drugmaker made an appeal to the U.S. court immediately but was denied. With the patent out of the way, other companies, like Pfizer will be ready to move forward and seek to take a slice of the $2.6 billion pie that Zytiga earned for J&J in 2016.
Here’s a roundup of these stories and other top legal news from the past month.
- Johnson & Johnson Gets Hit After Court Invalidates Cancer Patent, Making Room for Rivals
- New Details Emerge on the Murder of Apotex Founder and Wife
- Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS (linaclotide) Patent Litigation
- Struggling Teva Gets Another Hit, Fined for Foreign Bribes
- Eisai: Patent Infringement Litigation for Antiemetic Agent ALOXI in the U.S.
Read More From Karl Thiel:
Get Ready for the M&A Explosion
